Monday, August 21, 1995
Biogen Inc. announced its long-awaited gene therapy collaboration, with Genovo Inc, a
one-person startup associated with James Wilson, director of the Institute for Human Gene
Therapy at the University of Pennsylvania.
BGEN (Cambridge, Mass.) will invest more than $35 million in Genovo over five years,
including an undisclosed equity interest and milestone payments. BGEN received exclusive
worldwide rights to certain gene therapy products, including products for cystic fibrosis
and familial hypercholesterolemia (FH) and up to 20 additional products targeting diseases
of the liver and lung. Genovo will receive a royalty on sales.